I know there are many who disagree, but I think it is wrong. We’ll see soon enough where other big biopharma stand in this debate. I assume inclisiran hit CVOT, but magnitude is uncertain. There is no way I would bet it reaches 25% based on the other 2 PCSK9 CVOTs. Now has to take consideration Vascepa can somewhat impact trial result, don’t think they can really exclude some people who are going to take Vascepa.
Market Data 
Markets 
AI
